Influenza hemagglutinin and neuraminidase variants

Details Influenza hemagglutinin and neuraminidase variants Influenza hemagglutinin and neuraminidase variants

2009-01-15

2010-06-29

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S209100, C424S210100, C435S235100, C435S239000

Reexamination Certificate

active

07744901

ABSTRACT:
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.

REFERENCES:
patent: 3992522 (1976-11-01), Chanock et al.
patent: 4071618 (1978-01-01), Konobe et al.
patent: 4634666 (1987-01-01), Engleman et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5690937 (1997-11-01), Parkin
patent: 5716821 (1998-02-01), Wertz
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5820871 (1998-10-01), Palese et al.
patent: 5840520 (1998-11-01), Clarke
patent: 5854037 (1998-12-01), Palese et al.
patent: 5922326 (1999-07-01), Murphy
patent: 6001634 (1999-12-01), Palese et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6090391 (2000-07-01), Parkin
patent: 6146642 (2000-11-01), Garcia-Sastre et al.
patent: 6146873 (2000-11-01), Kistner et al.
patent: 6168943 (2001-01-01), Rose
patent: 6951754 (2005-10-01), Hoffmann
patent: 7037707 (2006-05-01), Webster et al.
patent: 2002/0119445 (2002-08-01), Parkin
patent: 2002/0164770 (2002-11-01), Hoffmann
patent: 2003/0035814 (2003-02-01), Kawaoka
patent: 2003/0147916 (2003-08-01), Ferko
patent: 2004/0029251 (2004-02-01), Hoffman et al.
patent: 2004/0137013 (2004-07-01), Katinger
patent: 2005/0042229 (2005-02-01), Yang
patent: 2005/0266026 (2005-12-01), Hoffmann
patent: 0 702 085 (1996-03-01), None
patent: 0 863 202 (1998-09-01), None
patent: 0 864 645 (1998-09-01), None
patent: 0 780 475 (1999-06-01), None
patent: 1826269 (2007-08-01), None
patent: WO-91-03552 (1991-03-01), None
patent: WO-93-21306 (1993-10-01), None
patent: WO-96-10632 (1996-04-01), None
patent: WO-96-34625 (1996-11-01), None
patent: WO-97-06270 (1997-02-01), None
patent: WO-97-12032 (1997-04-01), None
patent: WO-98-02530 (1998-01-01), None
patent: WO-98-13501 (1998-04-01), None
patent: WO-98-53078 (1998-11-01), None
patent: WO-99-02657 (1999-01-01), None
patent: WO-99-15672 (1999-04-01), None
patent: WO-00-53786 (2000-09-01), None
patent: WO-00-60050 (2000-10-01), None
Gorkova et al (Journal of Virology 79:2191-2198, Feb. 2005).
Genbank locus AAW80717.1 (Feb. 9, 2005).
AAW80723.1 (Feb. 9, 2005).
Li et al (Journal of Infectious Diseases 179:1132-8, 1999) (in IDS).
Banerjee and Barik, 1992, “Gene expression of vesicular stomatitis virus genome RNA”, Virology, 188:417-428.
Baron and Barrett, 1997, “Rescue of Rinderpest Virus from Cloned cDNA”, J. Virol. 71:1265-1271.
Basler et al., 1999, “Mutation of Neuraminidase Cysteine Residues Yields Temperature-Sensitive Infuenza Viruses”, J. of Virology 73(10):8095-8103.
Beare et al., 1975, “Trials in Man with Live Recombinants Made from A/PR/8/34 (HO N1) and Wild H3 N2 Influenza Viruses”, Lancet 729-732.
Belshe et al. 1998 , “The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children ,” N Engl J Med 338:1405-12.
Belshe, 1995 “A Review of Attenuation of Influenza Viruses by Genetic manipulation”, American Journal of Respiratory and Critical Care Medicine 152:S72-S75.
Bender et al., 1999, “Characterization of the surface proteins of influenza A (H5N1) viruses . . . ”, Virology 254(1):115-23.
Bergmann, et al., 1995, “The relative amount of an influenza A virus segment present in the viral particle is not affected . . . ”, J. of Gen. Virology, 76:3211-3215.
Boyce et al., 2000, “Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults”, Vaccine 19:217-26.
Boyer et al., 1994,“Infectious transcripts and cDNA clones of RNA viruses”, Virology, 198:415-26.
Brandt et al., 2001, “Molecular Determinants of Virulence, Cell Tropism, and Pathogenic Phenotype of Infectious Bursal Disease Virus”, Journal of Virology 75(24):11974-11982.
Brigden and Elliott, 1996, “Rescue of a Segmented Negative-Strand RNA Virus Entirely from Cloned Complementary DNAS”, Proc. Natl. Acad. Sci. USA 93:15400-15404.
Buchholz et al., 1999, “Generation of Bovine Resp. Syncytial Virus (BRSV) from cDNA:BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture . . . ”, J. Virol. 73:251-259.
Bukreyev et al., 1996, “Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene”, J. Virol. 70(10):6634-41.
Castrucci et al., 1995, “Reverse genetics system for generation of an influenza A virus mutant containing a deletion of the carboxyl-terminal M2 . . . ”. J.. Virol. 69(5):2725-2728.
Chen et al., 1999, “Influenza A virus NSI protein targets poly (A)-binding protein II of the cellular 3′-end processing machinery”, EMBO 18:2273-2283.
Clarke et al., 2000, “Rescue of mumps virus from cDNAJ”, J. Virol. 74(10):4831-4838.
Collins et al., 1991, “Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations”, Proc. Natl.. Acad. Sci. USA 88:9663-9667.
Collins et al., 1995, “Production of infectious human respiratory syncytial virus from cloned cDNA confirms and essential role . . . ”, PNAS 92:11563-11567.
Collins et al., 1996, “Parainfluenza Viruses”, Fields Virology, Lippincott-Raven Publishers, Phila., pp. 1205-1241.
Conzelmann et al., 1994, “Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins”, J. Virol. 68(2):713-719.
Conzelmann et al., 1996, “Genetic engineering of animal RNA viruses”, Trends Microbiol. 4(10):386-393.
Conzelmann et al., 1998, “Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes”, Ann. Rev. Genet. 32:123-162.
Conzelmann, 1996, “Genetic manipulation of non-segmented negative-strand RNA viruses”, J. Gen. Virol. 77 (Pt 3):381-389.
Cox, et al.; “Identification of Sequence Changes in the Cold-Adapted, Live Attenuated Influenza Vaccine Strain, A/Ann Arbor/6/60 (H2N2),” Virology, 1988; 167: 554-567.
Database Caplus on NCBI, Accession No. AY553802, Influenza A virus (A/little grebe/Thailand/Phichit-01/2004(H5N1) hemagglutinin (HA) gene, partial cds. May 21, 2004.
De and Banerjee, 1985, “Requirements and Functions of Vesicular Stomatitis Virus L and NS Proteins in the Transcription . . . ”, Biochem. & Biophys. Res. Communc. 126:40-49.
De and Banerjee, 1993, “Rescue of synthetic analogs of genome RNA of human parainfluenza virus type 3”, Virology, 96:344-348.
De and Banerjee, 1994, “Reverse genetics of negative strand RNA viruses”, Indian J. Biochem & Biophys. 31:367-376.
De et al., “Complete sequence of a cDNA clone of the hemagglutinin gene of influenza A/Chicken/Scotland/59 (H5N1) virus: comparison with contemporary North American and European strains”, Nucleic Acids Research, 1988. vol. 16, No. 9, pp. 4181-4182.
De et al., “Protection against virulent H5 avian influenza virus infection in chickens by an inactivated vaccine produced with recombinant vaccine virus”, Jun. 1988, Vaccine, vol. 6, pp. 257-261.
De la Luna et al., 1993, “Influenza virus naked RNA can be expressed upon transfection into cells co-expressing the three subunits . . . ”, J. Gen. Virol. 74:535-539.
De la Luna et al., 1995, Influenza virus NSI Protein Enhances the Rate of Translation Initiation of Viral mRNAs :, J. of Virol. 69:2427-2433.
Dimock et al., 1993, “Rescue of synthetic analogs of genomic RNA and replicative-intermed. RNA of human parainfluenza virus type 3”, J. Virol. 67(5):2772-2778.
Dreher and Hall, 1988, “Mutational Analysis of the Sequence and Structural Requirements in Brome Mosaic Virus RNA for Minus Strand Promoter Activity”, J. Mol. Biol. 201:31-40.
Dreher et al., 1984, “Mutant Viral RNAs Synthesized into vitro Show Altered Aminoacylation and Replicase Template Activities”, Nature 311:171-175.
Dunn et al., 1995, &#

Affiliated with

Also associated with

Rating

Influenza hemagglutinin and neuraminidase variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza hemagglutinin and neuraminidase variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza hemagglutinin and neuraminidase variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4245390